As part of its global expansion strategy, GB Sciences (OTCQB: GBLX) has launched a new Canada-based company that will develop cannabinoid medicines for medical cannabis, nutraceutical, and prescription drug markets.
The newly-launched company GBS Global Biopharma will focus on the development of clinical programs and intellectual property currently indicated for 60 disease and health conditions, notes a GB Sciences statement.
Why GBS Chose Canada
GBS Global will develop cannabinoid medicines for medical cannabis, nutraceutical, and prescription drug markets.
According to GB Sciences, the Canadian based company will operate in a fully legal environment, allowing for greater international collaboration, cross border expansion, access to capital, and cost-effective R&D supported by the country’s legal market, tax credits and favorable exchange rates.
“Canada’s policies will allow GBS Global to bring our next-generation cannabinoid medications to market quickly, safely and legally. Canada’s regulations, in particular, mean treatments can be evaluated and approved in less time than it would take in the U.S.,” GBS Global Chairman and GB Sciences CEO John Poss states.
“Developing our life sciences assets in Canada will expedite work to validate the safety and effectiveness of our proprietary therapeutics through expanded access to research partners and capital,” Dr. Andrea Small-Howard, the chief science officer of GBS Global, states.
“In addition, Canada’s medical cannabis legislation provides an alternative channel for supporting health claims on some of our OTC patent-pending formulas. Plus, these products can be exported to Europe, the world’s fastest growing market, ” Small-Howard notes.
GBS Global Cannabinoid Medications
GBS Global’s discovery platform is designed to generate “complex mixture” cannabinoid/terpenoid active ingredients for specific disease and health conditions. The company’s researchers are working with scientists in the U.S, Spain, and Greece on nutraceuticals, delivery technology, and prescription drug programs.
The company’s intellectual property portfolio of natural and synthetic cannabinoid-based complex mixtures are designed for Parkinson’s, neuropathic pain, and cardiac hypertrophy Rx programs in late pre-clinical stage of development.
Its OTC programs for irritable bowel syndrome, sleep disorders, and psoriasis are at formulation stage in step with ongoing discussions with strategic partners in the field.
